ContactIGES Pharma Germany & Switzerland
Local Insight. Global Impact.
Fabian Berkemeier, Managing Director Pharma & Biotech
German pharmaceutical landscape – highly regulated and stakeholder-driven
Successful entry and retention in the German pharmaceutical landscape requires deep insight into national regulatory frameworks, strategic foresight, and seamless execution in cooperation with key stakeholders to master various challenges such as:
- Complex stakeholder environment from physicians to patients to payers demanding tailored communication and alignment
- Strong health technology assessment (HTA) framework led by the Federal Joint Committee (G-BA) and IQWiG alongside tight pricing control
- Rising evidence expectations: real-world data, long-term and patient-relevant outcomes are increasingly essential, particularly for high-cost and innovative therapies
- Increasing cost and regulatory pressure: growing budget constraints, rebate contracts, and policy reforms limit pricing flexibility and planning certainty.
As part of the IGES Pharma Group, IGES Pharma Germany leverages extensive expertise to provide tailored solutions that address these market specificities, ensuring optimal product positioning through integrated solutions across market access strategy, evidence generation, pricing and reimbursement, launch execution, and lifecycle management. By getting fit for German HTA and market access, we prepare our clients for one of the driving European markets.
Respective services are provided through our German offices in Berlin and Nuremberg, as well as through our affiliate HealthEcon AG, Basel. As part of the IGES Group, HealthEcon not only provides abovementioned services for Germany but also extends our perspective to Switzerland as an independent yet strategically connected market – especially with regard to international price referencing and launch planning.
Guiding you every step of the way
From early market access strategy to launch management to evidence generation, we support biopharma companies navigate the highly regulated German market with structure, targeted approaches and tangible results.
1. Market Access Strategy
- Gap analysis of HTA evidence
- Evidence planning
- HTA agency consultations
- Stakeholder identification and consultation for HTA optimization
- HTA stress tests
2. Launch Management
- Evidence generation and reporting
- Assessment of early access programs
- Identification and approach of key opinion leaders (KOLs) for price prediction
- Price estimations, cost modeling and launch sequencing
- Full service HTA submissions
- Compilation of value dossiers
- Training for HTA hearings and preparation of written statements
- Pricing strategy and negotiation training
3. Evidence Generation
- Real-world evidence (RWE) concept development, study implementation and evaluation
- Full clinical research organization (CRO) services
- Payer contracting, managed entry agreement (MEA) and pay for outcome (P4O)
- Ring-fence financing instruments
- Engagement of policy & governmental stakeholders
Why IGES Pharma
- Integrated Support: From strategy to execution, we offer seamless guidance through every phase of your product’s journey.
- Tailored Approach: We adapt our frameworks to your specific product, disease area, and company needs.
- Global Alignment with Local Focus As part of IGES Pharma Group, we ensure your strategy is locally tailored and globally aligned.
Let's Make Access Happen
How to Contact Our Team:
pharma@iges.com
Berlin Office: Friedrichstraße 180, 10117 Berlin, Germany
Nuremberg Office: Marientorgraben 9, 90402 Nuremberg, Germany
Basel Office: HealthEcon AG, Steinentorstraße 19, 4051 Basel, Switzerland
